Adjuvant chemotherapy in elderly patients with breast cancer: a survey of the Breast International Group (BIG)

被引:45
作者
Biganzoli, L
Goldhirsch, A
Straehle, C
Castiglione-Gertsch, M
Therasse, P
Aapro, M
Minisini, A
Piccart, MJ
机构
[1] Inst Jules Bordet, B-1000 Brussels, Belgium
[2] European Inst Oncol, Milan, Italy
[3] BIG Secretariat, Brussels, Belgium
[4] IBCSG Coordinating Ctr, Bern, Switzerland
[5] Eortc Data Ctr, Brussels, Belgium
[6] EORTC, IDBBC, Brussels, Belgium
关键词
adjuvant chemotherapy; breast cancer; elderly; geriatric oncology; survey;
D O I
10.1093/annonc/mdh062
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: To collect oncologists' experience and opinion on adjuvant chemotherapy in elderly breast cancer patients. Materials and methods: A questionnaire was circulated among the members of the Breast International Group. Results: A total of 277 oncologists from 28 countries participated in the survey. Seventy years is the age cutoff commonly used to define a patient as elderly. Biological age and the biological characteristics of the tumor are the most frequently used criteria to propose adjuvant chemotherapy to an elderly patient. Combination therapy with cyclophosphamide, methotrexate and fluorouracil on days I and 8 is the most frequently prescribed regimen. Great interest exists in oral chemotherapy. Conclusion: There is interest among those who responded to the survey to validate a comprehensive geriatric assessment for use as a predictive instrument of toxicity and/or activity of anticancer therapy and to evaluate the role of a treatment option that is potentially less toxic and possibly as effective as polychemotherapy.
引用
收藏
页码:207 / 210
页数:4
相关论文
共 19 条
[1]  
Abe O, 1998, LANCET, V352, P930
[2]   Epidemiology of breast cancer in older women - Implications for future healthcare [J].
Alberg, AJ ;
Singh, S .
DRUGS & AGING, 2001, 18 (10) :761-772
[3]   Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis [J].
Cole, BF ;
Gelber, RD ;
Gelber, S ;
Coates, AS ;
Goldhirsch, A .
LANCET, 2001, 358 (9278) :277-286
[4]   Duration of adjuvant chemotherapy for breast cancer:: a joint analysis of two randomised trials investigating three versus six courses of CMF [J].
Colleoni, M ;
Litman, HJ ;
Castiglione-Gertsch, M ;
Sauerbrei, W ;
Gelber, RD ;
Bonetti, M ;
Coates, AS ;
Schumacher, M ;
Bastert, G ;
Rudenstam, CM ;
Schmoor, C ;
Lindtner, J ;
Collins, J ;
Thürlimann, B ;
Holmberg, SB ;
Crivellari, D ;
Beyerle, C ;
Neumann, RLA ;
Goldhirsch, A .
BRITISH JOURNAL OF CANCER, 2002, 86 (11) :1705-1714
[5]   Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer:: The International Breast Cancer Study Group Trial VII [J].
Crivellari, D ;
Bonetti, M ;
Castiglione-Gertsch, M ;
Gelber, RD ;
Rudenstam, CM ;
Thürlimann, B ;
Price, KN ;
Coates, AS ;
Hürny, C ;
Bernhard, J ;
Lindtner, J ;
Collins, J ;
Senn, HJ ;
Cavalli, F ;
Forbes, J ;
Gudgeon, A ;
Simoncini, E ;
Cortes-Funes, H ;
Veronesi, A ;
Fey, M ;
Goldhirsch, A .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (07) :1412-1422
[6]   Assessment of the older cancer patient [J].
Extermann, M ;
Aapro, M .
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2000, 14 (01) :63-+
[7]  
FARGEOT P, 2002, P AN M AM SOC CLIN, V21, pA37
[8]   MINI-MENTAL STATE - PRACTICAL METHOD FOR GRADING COGNITIVE STATE OF PATIENTS FOR CLINICIAN [J].
FOLSTEIN, MF ;
FOLSTEIN, SE ;
MCHUGH, PR .
JOURNAL OF PSYCHIATRIC RESEARCH, 1975, 12 (03) :189-198
[9]  
Goldhirsch A, 2002, JNCI-J NATL CANCER I, V94, P1054
[10]   EORTC 10968:: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx®, Doxil®) at a 6-week interval in patients with metastatic breast cancer [J].
Hamilton, A ;
Biganzoli, L ;
Coleman, R ;
Mauriac, L ;
Hennebert, P ;
Awada, A ;
Nooij, M ;
Beex, L ;
Piccart, M ;
Van Hoorebeeck, I ;
Bruning, P ;
de Valeriola, D .
ANNALS OF ONCOLOGY, 2002, 13 (06) :910-918